Brian Rini, MD, is leading a study launched by the National Cancer Institute (NCI) that will closely monitor cancer patients who acquire COVID-19 with the goal of providing highly detailed data to guide future care.

Researchers at Vanderbilt University Medical Center and Case Western Reserve University in Cleveland have been awarded a five-year, $3.3 million grant by the National Cancer Institute to apply artificial intelligence (AI) to help customize treatment for oral cancer patients.

Treatment with convalescent plasma vastly improved the survival rate of patients hospitalized for COVID-19 who also had hematologic malignances that compromise the immune system, according to new data released by the COVID-19 and Cancer Consortium (CCC19).

TG-Interacting Factor 1 (TGIF1) is a protein that regulates self-renewal of hematopoietic stem cells, which give rise to other blood cells, and which affects proliferation and differentiation of myeloid cells.

Mariana Byndloss, DVM, PhD, assistant professor of Pathology, Microbiology and Immunology, has received a V Scholar Award from the V Foundation for Cancer Research.

A team of Vanderbilt investigators has discovered that blocking a certain signaling pathway boosts antitumor immunity and reduces tumor growth and metastasis in models of breast cancer and melanoma.

David Cortez, PhD, Richard N. Armstrong Professor of Innovation in Biochemistry and professor of biochemistry, has been named interim chair in the Department of Biochemistry beginning Jan. 1, 2021.

For the second time, cancer researchers at Vanderbilt have discovered a protein that—when genetically manipulated to impede it from interacting with a gene responsible for cancer genesis—effectively melts tumors in days.

Transcription factors — proteins that regulate gene expression — play critical roles in cell fate decisions and are frequent targets of mutation in a variety of human cancers.

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration is being tested in a phase 3 clinical trial at Vanderbilt-Ingram Cancer Center.